Disseminated aspergillosis due to Aspergillus flavus in an experimental model: Efficacy of azole therapy

Mycoses

Volumn 46, Issue 5-6, 2003, Pages 174-182

  Kaliamurthy, J ^a   Geraldine, P ^b   Thomas, Philip A ^a  

^a JOSEPH EYE HOSPITAL   (India)

^b BHARATHIDASAN UNIVERSITY   (India)

Author keywords

Animal model; Antimycotic chemotherapy; Aspergillus flavus; Fluconazole; Itraconazole; Rat

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNE DEFICIENCY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; BRAIN; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FLUCONAZOLE; ITRACONAZOLE; KIDNEY; LIVER; LUNG; MALE; RATS; RATS, WISTAR;

ANIMALIA; ASPERGILLUS FLAVUS; RATTUS NORVEGICUS;

EID: 0038729393     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0507.2003.00865.x     Document Type: Article

References (53)

1. Leenders ACAP, Belkum AV, Behrendt M, Luijendijk AD, Verbrugh HA. Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection. J Clin Microbiol 1999; 37: 1752-57.
2. Seeliger HPR, Tintelnot, K. Epidemiology of aspergillosis. In: den Bossche H, Mackenzie DWR, Cauwenbergh G (eds), Aspergillus and Aspergillosis. New York: Plenum Press, 1988: pp. 23-24.
3. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
4. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732-8.
5. van Cutsem J, van Gerven F, Janssen PAJ. The antifungal activity in vitro of saperconazole (R 66 905). Preclinical research report on R 66 905 no.1. Beerse: Janssen Research Foundation, 1987.
6. Schmitt HJ, Bernard EM, Hauser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32: 1676-79.
7. van Cutsem J, van Gerven F, Janssen PAJ. Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother 1989; 33: 2063-68.
8. Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 1991; 35: 1329-33.
9. Niki Y, Bernard EM, Edwards FF, Schmitt HJ, Yu B, Armstrong D. Model of recurrent pulmonary aspergillosis in rats. J Clin Microbiol 1991; 29: 1317-22.
10. Rinaldi M. Invasive aspergillosis. Rev Infect Dis 1983; 5: 1061-77.
11. Ford S, Friedman L. Experiental study of the pathogenicity of aspergilli for mice. J Bacteriol 1967; 94: 928-33.
12. Jensen HE, Schonheyder H. Immunofluorescence staining of hyphae in the histopathological diagnosis of mycoses in cattle. J Med Vet Mycol 1989; 27: 33-44.
13. Pandita A, Sadana JR, Asrani RK. Studies on clinical signs and haematological alterations in pneumonic aspergillosis due to Aspergillus flavus in Japanese quail. Mycopathologia 1991; 116: 119-23.
14. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 38: 310-44.
15. Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Advances in Pharmacol 1997; 39: 143-89.
16. Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukemia. J Antimicrob Chemother 1991; 28, 555-60.
17. Persat F, Marzullo C, Guyotat D, Rochet MJ, Piens MA. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28: 838-41.
18. Troke PF, Marriott MS, Richardson K, Tarbit MH. In vitro potency and in vivo activity of azoles. Ann New York Acad Sci 1988; 544: 284-93.
19. Kowalsky SF, Dixon DM. Fluconazole: a new antifungal agent. Clin Pharm 1991; 10: 179-94.
20. Thomas PA, Abraham DJ, Kalavathy CM, Rajasekaran J. Oral itraconazole therapy for mycotic keratitis. Mycoses 1988; 31: 271-79.
21. Finegold SM, Martin WJ. Bailey and Scott's Diagnostic Microbiology. St Louis: c.V.Mosby Pubs., 1982: 403-56.
22. Emmons CW, Binford CH, Utz JP, Kwon-Chung KJ. Medical Mycology. 3rd edn, Philadelphia: Lea & Febiger, 1977: 485-87.
23. Shadomy S, Espinel-Ingroff A, Cartwright RJ. Laboratory studies with antifungal agents: susceptibility tests and bioassays. In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ (eds), Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology, 1985: pp. 991-99.
24. Rippon JW. Medical Mycology: The Pathogenic Fungi and the Pathogenic Actinomycetes. 3rd edn. Philadelphia: W.B. Saunders Company, 1988.
25. Richard JL, Thurston JR, Feden WM, Pinello C. Recent studies on aspergillosis in turkey poults. Mycopathologia 1984; 87: 3-11.
26. Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Experimental Chemotherapy 1982; 28: 461-79.
27. Waldorf AR, Levtiz SM, Diamond RD. In vitro bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150: 752-60.
28. van Burik JAH, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998; 36: 3115-21.
29. Brown R Jr, Lake JR, Katzman BA et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 1996; 61: 666-67.
30. Dupont B, Huber M, Kim SJ, Bennett JE. Galactomannan antigenemia and antigenuria in aspergillosis: studies in atients and experimentally infected rabbits. J Infect Dis 1987; 155: 1-11.
31. Nawada R, Amitani R, Tanaka E et al. Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection. J Clin Microbiol 1996; 34: 1433-9.
32. Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 1997; 41: 2238-43.
33. de Repentigny L, Boushira M, ste.Morie L, Bosisio G. Detection of galactomannan antigenemia by enzyme immunoassay in experimental invasive aspergillosis. J Clin Microbiol 1987; 25: 863-7.
34. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990; 12: 1147-201.
35. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for disease caused by Aspergillus. CID 2000; 30: 696-709.
36. Denning DW, Lee JY, Hostetler JS et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-44.
37. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillsis by the NIAID mycoses study group criteria. Arch Intern Med 1997; 157: 1857-62.
38. de Repentigny L, Ratelle J, Leclerc JM et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42: 404-8.
39. Harrousseau JL, Dekker AW, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropaenia: a randomised, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887-93.
40. Denning DW, del Favero A, Gluckman E et al. The efficacy and tolerability of UK-109, 496 (voriconazole) in the treatment of invasive aspergillosis (abstract P552). In: Proceedings of the 13th Congress of the International Society for Human and Animal Mycology (Parma; Italy). Salsomaggiore Terme, Italy: International Society for Human and Animal Mycology, 1997: pp. 217.
41. Sekhon AS, Padhye AA, Garg AK, Hamir Z. Effects of culture media on the in vitro susceptibility of selected opportunistic fungi to fluconazole and itraconazole. Chemotherapy 1992; 38: 169-73.
42. van Cutsem J, van Gerven F, van de Ven MA, Borgers M, Janssen PAJ. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984; 26: 527-34.
43. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. New Eng J Med 1994; 330: 263-72.
44. Troke PF. Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infections. In: Fromtling RA, Prous JR (eds), Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona:, 1987: pp. 103-112.
45. Kawasaki K, Matsumura Y, Ogawa M, Tsugi A, Matsunaga T, Goto S. In vivo and in vitro antifungal activity of fluconazole. Japan J Antibiot 1991; 44: 552-61.
46. Patterson TF, George D, Miniter P, Andriole VT. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis 1991; 163: 575-80.
47. George D, Kordick D, Miniter P, Patterson TF, Andriole VT. Combination therapy in experimental invasive aspergillosis. J Infect Dis 1993; 168: 692-8.
48. Kawamori J, Tsuruta S, Yoshida T. Effect of fluconazole on Aspergillus infection associated with chronic granulomatous disease. Kansenshogaku-Zasshi 1991; 65: 1200-4.
49. Mizuguchi M, Nishi K, Amemiya T et al. Successful use of fluconazole against semi invasive pulmonary aspergillosis. Nippon-Kyobu Shikkan Gakkai Zasshi 1997; 35: 645-9.
50. Kujath P, Lerch K. New antimicrobial agents under clinical investigation, Secondary mycoses in surgery: treatment with fluconazole. Infection 1989; 17: 111-7.
51. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: 599-602.
52. Kappe R, Osterziel KJ, Rüchel R, Siehl S. Fluconazole in patients at risk from invasive aspergillosis. J Med Vet Mycol 1993; 31: 259-61.
53. Francis P, Walsh TJ. Approaches to management of fungal infections in cancer patients. Oncology (Huntingt) 1992; 6: 133-44.